Press Releases

Year

Oct 31 2016

Intec Pharma Granted Chinese Patent for Accordion PillTM Carbidopa / Levodopa

Strengthens protection for Intec Pharma's leading Parkinson's disease product currently in a global Phase III clinical trial Intec Pharma Ltd. (NASDAQ:NTEC) (TASE:INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform

Sep 07 2016

Intec Pharma to Participate in Upcoming September Conferences

Intec Pharma Ltd. (Nasdaq:NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Company management will participate at the Rodman & Renshaw 18th Annual Global Investment Conference taking place from

Sep 06 2016

Intec Pharma Granted European Patent for Accordion Pill™–Carbidopa / Levodopa

Fortifies protection for Intec Pharma's leading product for Parkinson's disease currently in a global Phase III clinical trial Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology,

Sep 01 2016

Intec Pharma Reports First Half 2016 Financial Results

Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, reports financial results for the three and six months ended June 30, 2016. Highlights of the first six months of 2016 and recent weeks

Aug 04 2016

Intec Pharma to Pursue Development of Accordion Pill for Cannabinoid Therapies

Phase 1 clinical trial to begin in first quarter 2017 Intec Pharma Ltd. (Nasdaq:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a new clinical development program for its

Jun 03 2016

Intec Pharma Announces Planned Management Changes

JERUSALEM, June 3, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced today that Mr. Oren Mohar, the company's Chief Financial Officer, has

May 31 2016

Intec Pharma Receives Approval for US$5.2 Million Grant

JERUSALEM, May 31, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, announced today that the Israeli National Authority for

May 16 2016

Intec Pharma to Nominate Dr. John W. Kozarich as Chairman of the Board of Directors

JERUSALEM, May 16, 2016 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC; TASE: INTP), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, announced today that the board of directors of the company

May 03 2016

Intec Pharma Appoints VP of Clinical and Regulatory Affairs

JERUSALEM, May 3, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company, today announced the appointment of Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs. "Ms. Strauss-Levy has 15 years of experience in clinical

Apr 06 2016

Intec Pharma Expands Intellectual Property for AP-CDLD with Patent in South Korea

JERUSALEM, Israel, April 6, 2016 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the company has been informed that the Korean

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Next page
Last page

Displaying 51 - 60 of 74